



## **Analytica Ltd**

ACN 006 464 866

### **Entitlement Offer Booklet**

In relation to

**A pro-rata non-renounceable entitlement offer of 1 New Share for every 6 Shares held on the Record Date at an issue price of 0.5 cents per New Share to raise up to approximately \$2.7 million (before offer costs).**

The Entitlement Offer closes at 5pm (Sydney time) on Friday, 31 May 2019.

An investment in the Company should be considered speculative.

**This Entitlement Offer Booklet is important and should be read in its entirety. If you do not understand any part of this document or are in doubt as to what you should do, you should contact your professional adviser immediately. This document is provided for information purposes and is not a prospectus or other disclosure document under the Corporations Act.**

## TABLE OF CONTENTS

<b>Important Information .....</b>	<b>2</b>
<b>Message from the Chairman.....</b>	<b>3</b>
<b>Key Features of the Entitlement Offer .....</b>	<b>5</b>
1 Details of the Entitlement Offer.....	6
2 How to participate .....	9
3 Risk factors .....	13
4 Additional information .....	17
5 Definitions .....	20
<b>Corporate Directory .....</b>	<b>21</b>

## IMPORTANT INFORMATION

This Entitlement Offer is being made without a prospectus in accordance with section 708AA of the *Corporations Act 2001* (Cth) to shareholders with a registered address in Australia and New Zealand recorded in the register of members on 7pm (Sydney time) Wednesday, 15 May 2019 (**Record Date**).

This document is not a prospectus under Australian law or under any other law. Accordingly, this document does not contain all of the information which a prospective investor may require to make an investment decision, and it does not contain all of the information which would otherwise be required by Australian law or any other law to be disclosed in a prospectus.

This booklet may contain forward-looking statements, opinions and estimates. Forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this letter and the attached materials. You should not place undue reliance on these forward-looking statements. These forward-looking statements are based on information available to the Company as of the date of this letter. Except as required by law or regulation (including the ASX Listing Rules), the Company undertakes no obligation to update these forward-looking statements.

Before making any decision to invest, Eligible Shareholders must make their own investigations and analyses regarding the Company, its business, financial performance, assets, liabilities and prospects, rely on their own inquiries and judgements in the light of their own personal circumstances (including financial and taxation issues) and seek appropriate professional advice.

This booklet does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any 'US person' (as defined in Regulation S under the US Securities Act of 1933, as amended (US Person)). Shares may not be offered or sold in the United States or to, or for the account or benefit of, any US Person absent registration or an exemption from registration. This booklet has been prepared for publication only in Australia and New Zealand and may not be released elsewhere.

Capitalised terms have the meaning given to them in section 5.

## MESSAGE FROM THE CHAIRMAN

10 May 2019

Dear Shareholder

The Company announced on 10 May 2019, that it is conducting a 1 for 6, pro-rata, non-renounceable entitlement offer to Eligible Shareholders of new fully paid ordinary shares (**New Shares**) at an issue price of 0.5 cents per New Share (**Entitlement Offer**) to raise up to approximately \$2.7 million before offer costs.

The Company continues to be focussed on being deal-ready – by building a product that is best in class, gathering evidence that the product performance is exceptional and actively pursuing partnering opportunities. As advised at the last AGM, for our PeriCoach® product, we now feel we can offer the medical device companies a strategy that reduces their risks and at the same time enables the Company to get full value for our technology.

As part of its strategy to secure a transformational transaction and commercialise its technologies, the Company has, directly and through its corporate advisors, engaged in a number of discussions with potential counterparties. These discussions are in various stages of maturity, but all remain exploratory. The Company has not made any final decisions on any transaction structure or preferred commercial partner.

The outcomes of the Company's discussions are speculative. Shareholders should note that there is no certainty that any agreement will be reached or that any transaction will eventuate from any current or any future discussions or diligence enquiries. Shareholders are cautioned not to place undue reliance on these discussions in deciding whether to invest in the Company. Further announcements will be made by the Company if negotiations are completed and result in a binding agreement.

### Entitlement Offer

On behalf of your Directors, I am pleased to invite Eligible Shareholders to participate in the Entitlement Offer, further details of which are set out in section 1.1.

Eligible Shareholders are entitled to acquire 1 New Share for every 6 Shares held on the record date, being 7.00pm (Sydney time) on Wednesday, 15 May 2019 (**Record Date**).

### Additional New Shares

Eligible Shareholders may also apply for New Shares in excess of their Entitlement (**Additional New Shares**), with such oversubscriptions to be satisfied from Entitlements that were not taken up by other shareholders under the Entitlement Offer. The Directors reserve the right to allot and issue Additional New Shares in their absolute discretion.

Please see section 1.5 for further details on how Additional New Shares will be allocated to Eligible Shareholders.

### Use of funds

The funds raised under the Entitlement Offer will be used to fund the continued development and commercialisation of the Company's PeriCoach® system and AutoStart® and AutoFlush infusion system technologies, including potential commercial discussions with prospective commercialisation partners, and working capital.

### Actions required to take up your Entitlement

Your entitlement to subscribe for New Shares under the Entitlement Offer is set out in your personalised Entitlement and Acceptance Form accompanying this Offer Booklet. Instructions on how to participate in the Entitlement Offer are set out in section 2.

The Entitlement Offer closes at 5:00pm (Sydney time) on Friday, 31 May 2019, unless extended. To participate, you need to ensure that either your completed Entitlement and Acceptance Form and Application Money or your Application Money submitted to BPAY® are received before this time in accordance with the instructions set out on the form and in section 2.

If you take no action or your application is not supported by cleared funds, you will be deemed to have renounced your Entitlement. You should note that if you renounce all or part of your Entitlement, then your percentage shareholding in the Company will be diluted by your non-participation in the Entitlement Offer.

**Further information**

It is important that you carefully read this Entitlement Offer Booklet and the other publicly available information about the Company, including information on our website (<https://www.analyticamedical.com/>) and consider in particular the risk factors referred to in section 3 before making any investment decision.

The Analytica Board fully supports the Entitlement Offer, and I intend to take up 102,832,611 Shares under my entitlement.

On behalf of the Directors, I invite you to consider this opportunity and thank you for your continued support.

Yours faithfully

**Dr Michael Monsour**  
Chairman

## KEY FEATURES OF THE ENTITLEMENT OFFER

### Summary of Offer

Issue Price	0.5 cents per New Share
Entitlement	1 New Share for every 6 Shares held on the Record Date of 7pm (Sydney time) on Wednesday, 15 May 2019
Additional New Shares available	Eligible Shareholders may apply for New Shares in excess of their Entitlement. The Directors may scale back applications for Additional New Shares in their absolute discretion.
Maximum number of New Shares that can be issued under the Entitlement Offer	556,168,725 New Shares
Approximate number of Shares that will be on issue following the Entitlement Offer	3,893,181,075 Shares
Amount to be raised if the Entitlement Offer is fully subscribed (before costs)	Up to approximately \$2.7 million (before offer costs)

### Key dates

Record Date to determine Entitlements	7pm (Sydney time) Wednesday, 15 May 2019
This booklet and an Entitlement and Acceptance Forms despatched	Monday, 20 May 2019
Opening date of the Entitlement Offer	Monday, 20 May 2019
Closing Date — last date for lodgement of Entitlement and Acceptance Form and payment of Application Money	5pm (Sydney time) Friday, 31 May 2019
Trading of New Shares expected to commence on a deferred settlement basis	Monday, 3 June 2019
Issue of New Shares	Friday, 7 June 2019
Holding statements for New Shares expected to be despatched	Monday, 11 June 2019
Normal trading of New Shares expected to commence on ASX	

Eligible Shareholders that wish to participate in the Entitlement Offer are encouraged to subscribe for New Shares as soon as possible after the Entitlement Offer opens. The Company reserves the right, subject to the Corporations Act, the Listing Rules and other applicable laws, to vary the dates of the Entitlement Offer (including extending the Entitlement Offer or accepting late applications) without notice.

## 1 Details of the Entitlement Offer

### 1.1 The Entitlement Offer

Eligible Shareholders are invited to participate in a pro-rata, non-renounceable Entitlement Offer to raise up to approximately \$2.7 million (before offer costs).

The Entitlement Offer will be conducted on the basis of 1 New Share for every 6 Shares held on the Record Date, at an Issue Price of 0.5 cents per New Share, which is payable in full on application. Fractional entitlements will be rounded up.

### 1.2 Purpose of the Entitlement Offer

If fully subscribed, the Entitlement Offer will raise up to approximately \$2.7 million (before offer costs). The funds raised under the Entitlement Offer will be used to fund the continued development and commercialisation of the Company's PeriCoach® system and AutoStart® and AutoFlush infusion system technologies, including potential commercial discussions with prospective commercialisation partners, and working capital.

The Company's present intention is to use the funds raised under the Offers as follows:

Use of funds	If Entitlement Offer is 50% subscribed Amount (\$)	If Entitlement Offer is 75% subscribed Amount (\$)	If Entitlement Offer is fully subscribed Amount (\$)
Research and development	\$400,000	\$625,000	\$850,000
Product manufacturing and operating costs	\$50,000	\$75,000	\$100,000
Staff costs	\$500,000	\$750,000	\$1,000,000
Advertising and marketing	\$100,000	\$150,000	\$200,000
General working capital activities	\$200,000	\$325,000	\$450,000
Offer costs	\$100,000	\$100,000	\$100,000
<b>Total</b>	<b>\$1,350,000</b>	<b>\$2,025,000</b>	<b>\$2,700,000</b>

This table is illustrative only of the Company's present intention regarding use of funds. The precise activities that will be undertaken and the allocation of total funds raised may change without notice depending on market conditions and circumstances generally from time to time. There is no guarantee that funds raised will be applied precisely in the manner set out above or be sufficient to enable the Company to achieve its stated objectives.

### 1.3 Funding

The net cash outflows for the 9 month period from 1 July 2018 to 31 March 2019 was \$1,229,000. The estimated net cash outflow for the June 2019 quarter (excluding any new capital raising initiatives, including from the Entitlement Offer) is \$640,000. Cash and cash equivalents on hand as at 31 March 2019 was \$1,598,000.

The funds raised under the Entitlement Offer will be used for the purposes set out in section 1.2. There is no guarantee that the monies raised under the Entitlement Offer will be adequate or sufficient to meet the ongoing funding requirements of the Company under its current business plan or to achieve a breakeven point.

If the Company requires access to further funding at any stage in the future, there can be no assurance that additional funds will be available either at all or on terms and conditions which are commercially acceptable to the Company. If the Company is unable to obtain such additional capital, it may be required to reduce the scope of its anticipated activities, which could adversely affect its business, financial condition and operating results.

#### 1.4 **Eligible Shareholders**

This booklet contains an offer of New Shares to Eligible Shareholders. Eligible Shareholders are those holders of Shares who:

- (a) are registered as a holder of Shares on the Record Date;
- (b) have a registered address in Australia and New Zealand;
- (c) are not in the United States, are not a US Person and are not acting for the account or benefit of a person in the United States or a US Person; and
- (d) are eligible under all applicable securities laws to receive an offer under the Entitlement Offer.

The Entitlements of Eligible Shareholders who also hold options to subscribe for Shares will be calculated on the basis of the number of Shares they hold on the Record Date, disregarding any options which have not been exercised before that time.

Shareholders that are not Eligible Shareholders are Ineligible Shareholders.

#### 1.5 **Additional New Shares**

Eligible Shareholders that have fully subscribed for their Entitlements under the Entitlement Offer will be able to subscribe for additional shares (**Additional New Shares**). Additional New Shares will be sourced from Entitlements that were not taken up under the Entitlement Offer.

Eligible Shareholders can subscribe for Additional New Shares by completing the relevant part of the Entitlement and Acceptance Form, or through BPAY®.

There is no guarantee that those Eligible Shareholders will receive the number of Additional New Shares applied for, or any. The number of Additional New Shares will not exceed the shortfall from the Entitlement Offer. The Directors reserve the right to allot and issue Additional New Shares in their absolute discretion.

#### 1.6 **Placement of Shortfall Shares**

To the extent that any Shortfall Shares remain at the Closing Date, the Board also reserves the right to place any Shortfall Shares at their discretion within three months after the Closing Date.

#### 1.7 **Ranking of New Shares**

New Shares and Additional New Shares issued under the Entitlement Offer will rank equally with existing Shares.

#### 1.8 **Withdrawal of Entitlement Offer**

The Board reserves the right to withdraw all or part of the Entitlement Offer at any time before the issue of New Shares, in which case the Company will refund Application Money without payment of interest.

#### 1.9 **No cooling off rights**

Cooling off rights do not apply to an investment in New Shares. You cannot withdraw your application or payment once it has been accepted, except as allowed by law.

#### 1.10 **No Entitlements trading**

Entitlements are non-renounceable and will not be tradeable on ASX or otherwise transferable. Shareholders who do not take up their Entitlement in full will not receive any value in respect of those Entitlements that they do not take up.

**1.11 Minimum subscription**

There is no minimum subscription for the Entitlement Offer.

**1.12 Underwriting**

The Entitlement Offer is not underwritten.

**1.13 Risks**

There are a number of risks associated with the Company's business plan and the Entitlement Offer. These risks are set out in section 3 of this Entitlement Offer Booklet. An investment in New Shares involves various risks, a number of which are specific to Analytica and the industry in which it operates. An investment in New Shares should be regarded as speculative.

**1.14 Opening and Closing Date for applications**

The Entitlement Offer opens for acceptances on **Monday, 20 May 2019** and all Entitlement and Acceptance Forms and payments of Application Money must be received by no later than 5pm (Sydney time) on **Friday, 31 May 2019**, subject to the Directors being able to vary the Closing Date in accordance with the Listing Rules.

**1.15 Allotment of New Shares and ASX quotation**

It is expected that allotment of the New Shares will take place as soon as practicable after the Closing Date. It is expected that the New Shares will be allotted no later than **Friday, 7 June 2019**. However, if the Closing Date is extended, the date for allotment may also be extended. No allotment of New Shares will be made until permission is granted for their quotation by ASX.

**1.16 Information availability**

Eligible Retail Shareholders can obtain a copy of this Entitlement Offer Booklet from the Analytica website at <https://www.analyticamedical.com/> or by calling the Share Registry on 1300 795 998 (within Australia) or +61 1300 795 998 (outside Australia) at any time from 8:30am to 5:00pm on a Business Day during the Entitlement Offer period. Persons who access the electronic version of this Entitlement Offer Booklet should ensure that they download and read the entire Entitlement Offer Booklet. The electronic version of this Entitlement Offer Booklet will not include an Entitlement and Acceptance Form. A replacement Entitlement and Acceptance Form can be requested by calling the Share Registry.



## 2 How to participate

---

### 2.1 What you may do — choices available

Before taking any action you should carefully read this Entitlement Offer Booklet and the other publicly available information about the Company on our website (<https://www.analyticamedical.com/>) and consider the risk factors set out in section 3.

The number of New Shares to which Eligible Shareholders are entitled is shown on the Entitlement and Acceptance Form. If you are an Eligible Shareholder you may:

<b>Alternatives</b>	<b>See section</b>
Take up your Entitlement in full or in part	2.2
Take up your Entitlement in full and apply for Additional New Shares	2.2 and 2.3
Allow your Entitlement to lapse	2.7

### 2.2 If you wish to accept your Entitlement in full or in part

Either:

#### **Payment by cheque or bank draft**

If you are paying for your New Shares by cheque, bank cheque or bank draft, complete and return the Entitlement and Acceptance Form with your payment. The Share Registry must receive your completed Entitlement and Acceptance Form together with full payment for the number of New Shares for which you are applying by no later than **5pm (Sydney time) on Friday, 31 May 2019**.

Your cheque, bank cheque or bank draft must be paid in Australian currency and be drawn on an Australian branch of an Australian financial institution. Your payment must be for the full amount required to pay for the New Shares applied for. Payments in cash will not be accepted.

Cheques must be made payable to 'AnalyticaLtd' and crossed 'Not Negotiable'.

You must ensure that your cheque account has sufficient funds to cover your payment, as your cheque will be presented for payment on receipt. If your bank dishonours your cheque your application will be rejected. We will not re-present any dishonoured cheques.

or:

#### **Pay by BPAY®**

If you are paying for your New Shares by BPAY®, please refer to your personalised instructions on your Entitlement and Acceptance Form. Please note that should you choose to pay by BPAY®:

- you do not need to complete or return the Entitlement and Acceptance Form but are taken to have made the declarations on that personalised Entitlement and Acceptance Form;
- amounts received by the Company in excess of the Issue Price multiplied by your Entitlement (**Excess Amount**) may be treated as an application to apply for as many Additional Shares as your Excess Amount will pay for in full; and
- if you do not pay for your full Entitlement, you are deemed to have taken up your Entitlement in respect of such whole number of New Shares as is covered in full by your Application Money.

When completing your BPAY® payment, please make sure to use the specific Biller Code and unique reference number provided on your personalised Entitlement and Acceptance Form. If you receive more than one personalised Entitlement and Acceptance Form (i.e. where you have multiple holdings), please only use the reference number specific to the Entitlement on that form. If you inadvertently use the same reference number for more than one of your Entitlements, you will be deemed to have applied only for New Shares on the Entitlement to which the reference number applies.

You should be aware that your own financial institution may implement earlier cut-off times with regard to electronic payment, and you should therefore take this into consideration when making payment. It is your responsibility to ensure that funds submitted through BPAY® are received by **5pm (Sydney time) on Friday, 31 May 2019**.

Excess Application Money that is not sufficient to subscribe for a number of New Shares or Additional New Shares multiplied by the Issue Price will be refunded to you except where that amount is less than \$2.00, in which case it will be retained by the Company. The method by which you receive the refund will be at the discretion of the Company. No interest will be paid to Eligible Shareholders on any Application Money received or refunded.

### 2.3 Applying for Additional New Shares

If you have applied to take up all of your Entitlement, you may also apply for Additional New Shares.

If you apply for Additional New Shares and your application is successful (in whole or in part), your Additional New Shares will be issued at the same time that other New Shares are issued under the Entitlement Offer. There is no guarantee that you will receive any Additional New Shares. The Directors reserve their right to allot and issue Additional New Shares in their absolute discretion. To the extent that any Shortfall Shares remain at the Closing Date, the Board also reserves the right to place any Shortfall Shares at their discretion within 3 months after the Closing Date.

### 2.4 Acceptance of the Entitlement Offer

By completing, and the Company receiving, your personalised Entitlement and Acceptance Form with the requisite Application Money or making a payment by BPAY®, you:

- (a) agree to be bound by the terms of this Entitlement Offer Booklet and the provisions of the Company's constitution;
- (b) authorise the Company to register you as the holder(s) of the New Shares allotted to you;
- (c) declare that all details and statements made in the Entitlement and Acceptance Form are complete and accurate;
- (d) declare that you are over 18 years of age and have full legal capacity and power to perform all your rights and obligations under the Entitlement Offer;
- (e) acknowledge that once the Company receives the Entitlement and Acceptance Form or your payment by BPAY®, you may not withdraw it except as allowed by law;
- (f) agree to apply for, and be issued with up to, the number of New Shares that your payment will pay for at the Issue Price of 0.5 cents per New Share;
- (g) authorise the Company and its officers or agents to do anything on your behalf necessary for the New Shares to be issued to you, including to act on instructions of the Share Registry upon using the contact details set out in the Entitlement and Acceptance Form;
- (h) declare that you were the registered holder(s) at the Record Date (**Wednesday, 15 May 2019**) of the Shares indicated on the Entitlement and Acceptance Form as being held by you on the Record Date;

- (i) acknowledge that the information contained in this Entitlement Offer Booklet is not investment advice or a recommendation that New Shares are suitable for you, given your investment objectives, financial situation or particular needs;
- (j) represent and warrant that the law of any place (other than Australia and New Zealand) does not prohibit you from being given this Entitlement Offer Booklet or making an application for New Shares; and
- (k) represent and warrant that you are an Eligible Shareholder and have read and understood this Entitlement Offer Booklet and the Entitlement and Acceptance Form and that you acknowledge the matters, and make the warranties and representations and agreements contained in this booklet and the Entitlement and Acceptance Form.

By completing, and the Company receiving, your personalised Entitlement and Acceptance Form with the requisite Application Money or making a payment by BPAY®, you will also be deemed to have acknowledged, represented and warranted on behalf of each person on whose account you are acting that:

- (a) you are not in the United States and are not a US Person (see section 4.1(b) below), and are not acting for the account or benefit of, a US Person and are not otherwise a person to whom it would be illegal to make an offer or issue New Shares under the Entitlement Offer;
- (b) you acknowledge that the Entitlements and the New Shares have not been, and will not be, registered under the US Securities Act or the securities laws of any state or other jurisdiction in the United States, or in any other jurisdiction outside Australia and New Zealand, and accordingly, the Entitlements may not be taken up, and the New Shares may not be offered, sold or otherwise transferred except in accordance with an available exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and any other applicable securities laws; and
- (c) you have not and will not send any materials relating to the Entitlement Offer to any person in the United States or that is a US Person, or is acting for the account or benefit of a US Person.

## 2.5 Payment for New Shares

The Issue Price of 0.5 cents per New Share is payable in full on application.

The Application Money payable for your Entitlement is set out on the Entitlement and Acceptance Form.

Application Money will be held in trust in a subscription account until allotment. Any interest earned on Application Money will be for the benefit of the Company and will be retained by the Company whether or not the allotment of New Shares takes place.

## 2.6 Address details and enquiries

Completed Entitlement and Acceptance Forms should be forwarded in the enclosed reply paid envelope to the Company's Share Registry by mail to the following address:

### **Mailing Address**

Analytica Limited  
C/- Link Market Services Limited  
GPO Box 3560  
Sydney, NSW 2001

### **Hand Delivery**

Analytica Limited  
C/- Link Market Services Limited  
1A Homebush Bay Drive  
Rhodes NSW 2138

**(Do not use this address for mailing purposes)**

Please note that payment of Application Money by BPAY® does not require the return of the Acceptance Forms.

If you would like further information you can contact your stockbroker, accountant or other professional adviser or call the Share Registry on 1300 795 998 (within Australia) or +61 1300 795 998 (outside Australia) at any time from 8:30am to 5:00pm on a Business Day during the Entitlement Offer period.

**2.7 If you do not wish to accept all or any part of your Entitlement**

To the extent you do not accept all or any part of your Entitlement, it will lapse.

Entitlements are non-renounceable and will not be tradeable on the ASX or otherwise transferable. Shareholders who do not take up their Entitlements in full will not receive any value in respect of the Entitlements they do not take up, and their percentage shareholding in the Company will be reduced following the issue of New Shares.

### 3 Risk factors

---

#### 3.1 General

There are a number of factors, both specific to the Company and of a general nature, which may affect the future operating and financial performance of the Company, its products, the industry in which it operates and the outcome of an investment in the Company. There can be no guarantee that the Company will achieve its stated objectives or that forward-looking statements will be realised.

This section describes certain, but not all, risks associated with an investment in the Company. Each of the risks set out below could, if it eventuates, have a material adverse impact on the Company's performance, profits and the value of its Shares.

Before deciding to invest in the Company, potential investors should read the entire Prospectus and the risk factors that could affect the financial performance of the Company.

You should carefully consider these factors in light of your personal circumstances and seek professional advice from your accountant, stockbroker or other professional adviser before deciding whether to invest.

#### 3.2 Specific risk factors

In addition to the general risks set out in section 3.1, the Directors believe that there are a number of specific factors that should be taken into account before investors decide whether or not to apply for Shares. Each of these factors could have a materially adverse impact on the Company, its business plan, operating and product strategies and its financial performance and position.

These include:

##### (a) Dilution risk

A total of 556,168,725 New Shares are proposed to be issued under this Entitlement Offer. Interests associated with Dr Monsour have advised that they intend to take up 102,832,611 Shares under the Entitlement Offer. If there is no participation from other Eligible Shareholders, interests of Shareholders other than interests associated with Dr Monsour could be diluted from 76.82% to 74.53%.

##### (b) Strategic Direction

The Company's strategic direction is to secure a transformational commercial transaction which may include a sale or commercial licence of its principal product lines, the sale of the company as a whole, a joint venture or broader commercial transaction. Based on advice from the Company's advisers and other market soundings, the Directors believe this is a realistically achievable objective.

There can be no assurance, however, that the Company will be able to secure such a commercial transaction, either at all or within the near term or on terms and conditions acceptable to the Company.

##### (c) Funding risk

The Company currently operates on a negative cash operating basis in that its operating expenses exceed its revenue. There is no guarantee that the monies raised under the Entitlement Offer will be adequate or sufficient to achieve its stated objectives or meet the funding requirements of the Company under its current business plan.

If the Company requires access to further funding at any stage in the future, there can be no assurance that additional funds will be available either at all or on terms and conditions which are commercially acceptable to the Company.

**(d) Product performance risk**

The Company continues to improve the PeriCoach® device and to conduct ongoing trials. The Company has also conducted a trial of its AutoStart® burette infusion system in Gladstone, Queensland. The results of those trials are positive and encouraging.

However, there is an inherent risk with any new technological device that the PeriCoach® device and AutoStart® burette does not function or perform as expected and if this occurs there will be a material adverse effect on the Company's prospects and business generally.

**(e) Intellectual property and patent risk**

The ability of the Company to maintain protection of its proprietary intellectual property and operate without infringing the proprietary intellectual property rights of third parties is an integral part of the Company's business. To protect its proprietary intellectual property, the Company has a number of registered trade marks and designs, and patents pending and granted in key markets.

There is a risk that some or all of the outstanding IP Applications may not be granted, and the Company may not be able to prevent other persons from using the Company's intellectual property.

The granting of protection such as a registered patent does not guarantee that the rights of third parties are not infringed or that competitors will not develop technology to avoid the patent. Patents are territorial in nature and patents must be obtained in each and every country where protection is desired. There can be no assurance that any patents which the Company may own or control will afford the Company significant protection of its technology or its products.

**(f) Reverse engineering risk and trade secret risk**

There is a risk of the Company's products being reverse engineered or copied. The Company relies on trade secrets to protect its proprietary technologies, especially where it does not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. The Company relies in part on confidentiality agreements with its employees, contractors, consultants, outside scientific collaborators and other advisors to protect its trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorised disclosure of confidential information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of the proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect the Company's competitive business position.

Analytica has also spent considerable resources building awareness with key opinion leaders in the incontinence and pelvic floor health fields through the interactions with our clinical advisory boards, and presence and demonstrations at internationally significant conferences and events. Analytica believes that clinician awareness or even endorsement of the PeriCoach™ system removes a barrier to sales, and is difficult to replicate.

**(g) Regulatory risk**

Government health regulations, which are subject to change, add uncertainty to obtaining approval to market medical devices and this risk increasingly also applies to mobile health applications that conform to certain device regulatory guidelines. There is a risk that the cost of compliance will exceed expectations and have an adverse impact on the financial position of the Company.

The United States and European Union are considered key markets by the Company. The Company has ARTG registration in Australia for urinary incontinence and pelvic organ prolapse, 510(k) clearance for the treatment of urinary incontinence to market the PeriCoach™ device in the US and its territories, and has CE-marking for incontinence and prolapse allowing European supply, with certain additional approvals required on a country-by-country basis. The Company does not intend to apply for registration in any other jurisdiction in the short to medium term. The Company and its suppliers must also comply with production quality systems and may be audited/investigated at any time by any international regulatory body. This may significantly impact on production, operational, and other project timelines, may incur significant compliance costs with an adverse impact on the financial position of the Company.

(h) **Commercialisation risk**

There can be no assurance that the Company's existing product or any new products or services that it develops will achieve market acceptance or will be commercialised, either on a timely basis or at all.

For example, the PeriCoach® product may not be able to be manufactured and sold at a price which gains market acceptance. The sensitive nature of the product means traditional marketing methods may be ineffective or cost-prohibitive. Alternative marketing methods may not achieve desired levels of market acceptance and sales.

New entrants to the industry or competing technologies that outperform the Company's products could be developed and successfully introduced, and as a result, there is a risk that the Company's products may not be able to compete effectively in its target markets.

An inability or material delay in the commercialisation of the Company's product would have an adverse impact on the revenue, financial performance, prospects and share price of the Company.

(i) **Manufacturing strategy**

The Company has adopted an outsourced manufacturing strategy to align with its current stage of operations. This manufacturing strategy has associated risks as the Company is unable to directly control delivery schedules, quality assurance, manufacturing yields and production costs. Problems in the Company's manufacturing and assembly processes could limit its ability to produce sufficient product to meet the demands of potential customers.

(j) **Warranty risk and product liability**

There is an inherent risk of defective workmanship or materials in the manufacture of the Company's products and for exposure to product liability for damages suffered by third parties attributable to the use of the product. Defective products may have a materially adverse impact on the Company's reputation, its ability to achieve sales and commercialise its products and on its financial performance due to warranty obligations.

(k) **Personnel risk**

The successful operation of the Company's business relies on its ability to retain experienced and high-performing key management personnel. The Company may not successfully retain existing, and/or attract new, key management personnel. The unexpected loss of any key management personnel, or the inability on the part of the Company to attract experienced personnel, may adversely affect the Company's ability to develop and implement its business strategies.

(l) **Information technology**

The Company relies on its computer hardware, software and information technology systems. Should these not be adequately maintained, secured or updated or the Company's disaster recovery processes not be adequate, system failures may negatively impact on its performance.

(m) **Dividends**

There is no guarantee as to future earnings of the Company or that the Company will be profitable at any time in the future and there is no guarantee that the Company will be in a financial position to pay dividends at any time in the future.

### 3.3 **General risk factors**

(a) **Share market**

On completion of the Entitlement Offer, the New Shares may trade on ASX at higher or lower prices than the Issue Price. Investors who decide to sell their New Shares after the Entitlement Offer may not receive the amount of their original investment. There can be no guarantee that the price of New Shares will increase after listing. The price at which the New Shares trade on ASX may be affected by the financial performance of the Company and by external factors over which the Directors and the Company have no control.

These factors include movements on international share and commodity markets, local interest rates and exchange rates, domestic and international economic conditions, government taxation, market supply and demand and other legal, regulatory or policy changes.

(b) **Dependence on general economic conditions**

The operating and financial performance of the Company is influenced by a variety of general economic and business conditions, including levels of consumer spending, inflation, interest rates and exchange rates, access to debt and capital markets, government fiscal, monetary and regulatory policies.

A prolonged deterioration in general economic conditions, including an increase in interest rates or a decrease in consumer and business demand, could be expected to have a material adverse impact on the Company's business or financial condition. Changes to laws and regulations or accounting standards which apply to the Company from time to time could adversely impact on the Company's earnings and financial performance.

(c) **Tax risk**

Any change to the rate of company income tax in jurisdictions in which the Company operates will impact on shareholder returns, as will any change to the rates of income tax applying to individuals or trusts. Any change to the tax arrangements between Australia and other jurisdictions could have an adverse impact on future earnings and the level of dividend franking. The Company has applied for and received research and development tax incentives. Compliance with the rules applicable to these incentives may be subject to audit by the ATO in the ordinary course.

(d) **Legislative and regulatory changes**

Legislative or regulatory changes, including health care regulations or changes in relation to products sold by the Company, could have an adverse impact on the Company.



## 4 Additional information

---

### 4.1 Shareholders outside Australia and New Zealand, general restrictions

This Entitlement Offer Booklet and accompanying Entitlement and Acceptance Form do not constitute an offer in any place in which, or to any person to whom, it would not be lawful to make such an offer.

No action has been taken to register or qualify the New Shares, or to otherwise permit an offering of New Shares, outside Australia and New Zealand. The New Shares may not be offered in a jurisdiction outside Australia and New Zealand, where such an offer is not made in accordance with the laws of that place, unless otherwise determined by the Directors.

The distribution of this Entitlement Offer Booklet in jurisdictions outside Australia or New Zealand may be restricted by law and therefore persons who come into possession of this document outside Australia and New Zealand, should seek advice on, and observe, any such restrictions. A failure to comply with these restrictions may constitute a violation of applicable securities laws.

It is the responsibility of any applicant to ensure compliance with any laws of the country relevant to their application. Return of a duly completed Entitlement and Acceptance Form and/or payment of Application Money will be taken by the Company to constitute a representation that there has been no breach of such laws and that the applicant is physically present in Australia and New Zealand.

#### (a) New Zealand securities law requirements

The New Shares are not being offered or sold to the public in New Zealand other than to existing shareholders of the Company with registered addresses in New Zealand to whom the offer of New Shares is being made in reliance on the *Financial Markets Conduct Act 2013* and the *Financial Markets Conduct (Incidental Offers) Exemption Notice 2016*.

This Entitlement Offer Booklet has been prepared in compliance with Australian law and has not been registered, filed with or approved by any New Zealand regulatory authority. This Entitlement Offer Booklet is not a product disclosure statement under New Zealand law and is not required to, and may not, contain all the information that a product disclosure statement under New Zealand law is required to contain.

#### (b) United States

The New Shares have not been, and will not be, registered under the US Securities Act or the securities laws of any state of the United States and may not be offered or sold, directly or indirectly, in the United States or to, or for the account or benefit of, a US person, except in a transaction exempt from the registration requirements of the US Securities Act and applicable United States securities laws.

This Entitlement Offer Booklet is neither an offer to sell nor a solicitation of an offer to buy securities as those terms are defined under the US Securities Act. The Entitlement Offer is not being made to US persons or persons in the United States.

### 4.2 Ineligible Shareholders

The Company is not extending the Entitlement Offer to Ineligible Shareholders having regard to the cost of complying with legal and regulatory requirements outside Australia and New Zealand, the number of Ineligible Shareholders and the number and value of New Shares which could be offered to Ineligible Shareholders.

Where this Entitlement Offer Booklet has been dispatched to Ineligible Shareholders, it is provided for information purposes only.

In limited circumstances the Company may elect to treat as Eligible Shareholders certain Shareholders who would otherwise be Ineligible Shareholders, provided the Company is satisfied that it is not precluded from lawfully issuing New Shares to such Shareholders either unconditionally or after compliance with conditions which the Board in its sole discretion regards as acceptable and not unduly onerous.

#### 4.3 **Taxation consequences**

The taxation consequences of any investment in New Shares will depend upon your particular circumstances. Potential investors must make their own enquiries concerning the taxation consequences of an investment in the Company. Applicants should consult their tax adviser for advice applicable to their individual needs and circumstances.

#### 4.4 **Privacy**

The information about Eligible Shareholders included on an Entitlement and Acceptance Form is used for the purposes of processing the Entitlement and Acceptance Form and to administer the Eligible Shareholder's holding of New Shares. By submitting an Entitlement and Acceptance Form, each Eligible Shareholder agrees that the Company may use the information provided by an Eligible Shareholder on the form for the purposes set out in this privacy statement and may disclose it for those purposes to the Share Registry and the Company's related bodies corporate, agents and contractors and third party service providers, including mailing houses and professional advisers, and to the ASX and other regulatory authorities.

The Corporations Act requires the Company to include information about each Shareholder (including name, address and details of the Shares held) in the Register. The information contained in the Register must remain there even if that person ceases to be a Shareholder. Information contained in the Register is also used to facilitate payments and corporate communications (including the Company's financial results, annual reports and other information that the Company wishes to communicate to its security holders) and compliance by the Company with legal and regulatory requirements.

Under the *Privacy Act 1988* (Cth), you may request access to your personal information held by, or on behalf of, the Company or the Share Registry. A fee may be charged for access. You can request access to your personal information by telephoning or writing to the Share Registry as follows:

**Link Market Services Limited**  
 Locked Bag A14  
 Sydney South NSW 2001  
 Ph: 1300 554 474

#### 4.5 **Not investment advice**

The Entitlement Offer complies with the requirements of section 708AA of the Corporations Act as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84.

This Entitlement Offer Booklet is not a prospectus under the Corporations Act and has not been lodged with ASIC. It is also not investment advice and does not take into account your investment objectives, financial situation, tax position and particular needs. Before deciding whether to apply for New Shares, you should consider whether they are a suitable investment for you in light of your personal circumstances (including financial and taxation issues) and seek professional guidance before deciding whether to invest.

#### 4.6 **Future performance and forward looking statements**

Except as required by law, and only to the extent so required, no person warrants or guarantees the future performance of the Company or any return on any investment made pursuant to this Entitlement Offer. Past Share price performance provides no guidance as to future Share price performance.

#### **4.7 Governing law**

This Entitlement Offer Booklet, the Entitlement Offer and the contracts formed on acceptance of applications are governed by the laws applicable in Queensland, Australia.

#### **4.8 Interpretation**

Some capitalised words and expressions used in this Entitlement Offer Booklet have meanings which are explained in section 5.

A reference to time in this Entitlement Offer Booklet is to the local time in Brisbane, Australia, unless otherwise stated. All financial amounts in this Entitlement Offer Booklet are expressed in Australian dollars, unless otherwise stated.

#### **4.9 Disclaimer of representations**

No person is authorised to provide any information, or to make any representation, in connection with the Entitlement Offer that is not contained in this Entitlement Offer Booklet.

Any information or representation that is not in this booklet may not be taken as having been authorised by the Company or its related bodies corporate in connection with the Entitlement Offer. Except as required by law, none of Analytica Ltd, or any other person, warrants or guarantees the future performance of Analytica Ltd or any return on any investment made in connection with this Entitlement Offer.

#### **4.10 Handling fees**

The Company may consider on a case by case basis paying handling fees of up to 1.5% by prior agreement to brokers for Entitlement and Acceptance Forms lodged by them on behalf of Eligible Shareholders.

#### **4.11 Participation by related parties**

The Chairman Dr Michael Monsour, and his associated entities, hold 773,374,845 Shares (representing approximately 23.18% of the total issued share capital of the Company). Dr Monsour has advised that he, and his associated entities, intend to take up 102,832,611 Shares under the Entitlement Offer, which will result in a total shareholding of 876,207,456 on completion of the Entitlement Offer.

## 5 Definitions

---

<b>Additional New Shares</b>	New Shares you apply for in excess of your Entitlement.
<b>Application Money</b>	Money paid by you for New Shares and Additional New Shares.
<b>ASIC</b>	The Australian Securities and Investments Commission.
<b>ASX</b>	ASX Limited ACN 008 624 691 or the Australian Securities Exchange, as applicable.
<b>Board</b>	The board of Directors from time to time.
<b>Closing Date</b>	5pm (Sydney time) on Friday, 31 May 2019.
<b>Company or Analytica</b>	Analytica Ltd ACN 006 464 866.
<b>Corporations Act</b>	<i>Corporations Act 2001</i> (Cth).
<b>Director</b>	A director of the Company.
<b>Eligible Shareholder</b>	A Shareholder on the Record Date and who is not an Ineligible Shareholder.
<b>Entitlement</b>	The entitlement to 1 New Share for every 6 Shares held on the Record Date. The entitlement of each Eligible Shareholder is shown on the personalised Entitlement and Acceptance Form.
<b>Entitlement and Acceptance Form</b>	The entitlement and acceptance form accompanying this Entitlement Offer Booklet.
<b>Entitlement Offer</b>	The offer of New Shares made in this Entitlement Offer Booklet.
<b>Entitlement Offer Booklet</b>	This booklet as varied, supplemented or replaced from time to time.
<b>Ineligible Shareholder</b>	A Shareholder with an address in the Register outside Australia or New Zealand.
<b>Issue Price</b>	0.5 cents per New Share.
<b>Listing Rules</b>	The official listing rules of ASX, as amended or waived by ASX from time to time.
<b>New Shares</b>	Shares to be allotted and issued under the Entitlement Offer including, as the context requires, any additional shares issued under any shortfall.
<b>Record Date</b>	7pm (Sydney time) on Wednesday, 15 May 2019.
<b>Register</b>	The register of Shareholders required to be kept under the Corporations Act.
<b>Share</b>	A fully paid ordinary share in the Company.
<b>Share Registry</b>	Link Market Services Limited.
<b>Shareholder</b>	A holder of Shares.
<b>Shortfall Shares</b>	New Shares available under the Entitlement Offer that are not subscribed for by Eligible Shareholders by the Closing Date.
<b>US or United States</b>	United States of America, its territories and possessions, any State of the United States of America and the District of Columbia.
<b>US Person</b>	The meaning given in Regulation S under the US Securities Act.
<b>US Securities Act</b>	The <i>United States Securities Act of 1933</i> , as amended.

## **CORPORATE DIRECTORY**

### **Directors and senior management**

Dr Michael Monsour – Non-Executive Chairman  
Dr Peter B. Corr – Non-Executive Director  
Dr Thomas Lönngren – Non-Executive Director  
Mr Ross Mangelsdorf – Executive Director and Chief Financial Officer  
Mr Geoff Daly – Chief Executive Officer  
Ms Chelsea Cornelius – Product Development and Operations Manager  
Ms Megan Henken – VP Global Marketing  
Mr Bryan Dulhunty – Company Secretary

### **Registered office**

c/o Avance Chartered Accountants  
222 Bazaar Street  
Maryborough QLD 4650  
Telephone: +61 7 3278 1950

### **Website**

<https://www.analyticamedical.com/>

### **Legal advisors**

Thomson Geer Lawyers  
Level 16, Waterfront Place  
1 Eagle Street  
Brisbane QLD 4000

### **Share Registry**

Link Market Services Limited  
Level 21  
10 Eagle Street  
Brisbane QLD 4000

### **Auditor**

Bentleys  
Level 9  
123 Albert Street  
Brisbane QLD 4000

# ANALYTICA

**Analytica Limited**  
ABN 12 006 464 866

All Registry communications to:  
Link Market Services Limited  
Locked Bag A14  
Sydney South NSW 1235 Australia  
Telephone: 1300 554 474  
From outside Australia: +61 1300 554 474  
ASX Code: ALT  
Website: [www.linkmarketservices.com.au](http://www.linkmarketservices.com.au)

**SRN/HIN:**

**Entitlement Number:**

**Number of Eligible Shares held as  
at the Record Date, 7:00pm (Sydney)  
on 15 May 2019:**

**Entitlement to New Shares  
(on a 1 New Share for 6 basis):**

**Amount payable on full acceptance  
at A\$0.005 per Share:**

<b>Offer Closes 5.00pm (Sydney time):</b>	<b>31 May 2019</b>
---	--------------------

## ENTITLEMENT AND ACCEPTANCE FORM

As an Eligible Shareholder you are entitled to acquire 1 New Share for every 6 Existing Shares that you hold on the Record Date, at an Offer Price of A\$0.005 per New Share. You may also apply for New Shares in excess of your Entitlement, at the Offer Price. This is an important document and requires your immediate attention. If you do not understand it or you are in doubt as how to deal with it, you should contact your accountant, stockbroker, solicitor or other professional adviser.

**IMPORTANT:** The Offer is being made under the Offer Booklet dated 10 May 2019. The Offer Booklet contains information about investing in the New Shares. Before applying for New Shares, you should carefully read the Offer Booklet. This Entitlement and Acceptance Form should be read in conjunction with the Offer Booklet.

If you do not have a paper copy of the Offer Booklet, you can obtain a paper copy at no charge, by calling the Analytica Limited Offer Information Line on 1300 795 998 (within Australia) or +61 1300 795 998 (from outside Australia).

### PAYMENT OPTIONS

If you wish to take up all or part of your Entitlement (as shown above), take up all or part of your Entitlement and apply for additional New Shares, you have two payment options detailed below.

#### OPTION 1: PAYING BY BPAY®

If paying by BPAY®, refer to the instructions overleaf. **You do NOT need to return the acceptance slip below if you elect to make payment by BPAY®.** Payment must be received via BPAY® before 5.00pm (Sydney time) on 31 May 2019. You should check the processing cut off time for BPAY® transactions with your bank, credit union or building society to ensure your payment will be received by the Registry in time. By paying by BPAY® you will be deemed to have completed an Application Form for the number of Shares subject to your application payment.

#### OPTION 2: PAYING BY CHEQUE, BANK DRAFT OR MONEY ORDER

If paying by cheque, bank draft or money order, complete and return the acceptance slip below with your Application Monies. No signature is required on the acceptance slip. The acceptance slip with your Application Monies must be received by the Registry before 5.00pm (Sydney time) on 31 May 2019.



**Biller Code:** [XXXXXXX]  
**Ref:**

#### Telephone & Internet Banking – BPAY®

Contact your bank or financial institution to make this payment from your cheque, savings, debit or transaction account. More info: [www.bpay.com.au](http://www.bpay.com.au)  
® Registered to BPAY Pty Ltd ABN 69 079 137 518

See overleaf for details and further instructions on how to complete and lodge this Entitlement and Acceptance Form.

**THIS IS A PERSONALISED FORM FOR THE SOLE USE OF THE SHAREHOLDER AND HOLDING RECORDED ABOVE.**



*Please detach and enclose with payment*



**SRN/HIN:**

**Entitlement Number:**

**A** Number of New Shares accepted (being not more than your Entitlement shown above)

**B** Number of additional New Shares

**C** Total number of New Shares accepted (add Boxes A and B)

**D PLEASE INSERT CHEQUE, BANK DRAFT OR MONEY ORDER DETAILS** – Cheques, bank drafts or money orders must be drawn on an Australian branch of a financial institution in Australian currency, made payable to “Analytica Limited” and crossed “Not Negotiable”.

Drawer

Cheque Number

BSB Number

Account Number

Amount of Cheque

**E CONTACT DETAILS** – Telephone Number

Telephone Number – After Hours

Contact Name

## ANALYTICA LIMITED

The Entitlement Offer to which this Entitlement and Acceptance Form relates is not being made to investors located or resident outside of Australia and New Zealand. In particular the Entitlement Offer is not being made to any person in the U.S. or to a U.S. person. The Offer Booklet and Entitlement and Acceptance Form do not constitute an offer or invitation to acquire Shares in any place in which, or to any person to whom, it would be unlawful to make such an offer or invitation.

### ACCEPTANCE OF ENTITLEMENT OFFER

By either returning the Entitlement and Acceptance Form with payment to the Registry, or making payment received by BPAY®:

- you represent and warrant that you have read and understood the Offer Booklet and that you acknowledge the matters, and make the warranties and representations;
- you provide authorisation to be registered as the holder of New Shares acquired by you and agree to be bound by the Constitution of Analytica Limited.

### HOW TO APPLY FOR NEW SHARES

#### 1. IF PAYING BY BPAY® (AVAILABLE TO SHAREHOLDERS WITH AN AUSTRALIAN BANK ACCOUNT ONLY)

If you elect to make payment using BPAY® you must contact your bank or financial institution to make this payment from your cheque, savings, debit or transaction account. For more information on paying by BPAY®: [www.bpay.com.au](http://www.bpay.com.au)

Work out the total amount payable by you. To calculate the total amount, multiply the number of New Shares you wish to apply for by A\$0.005.

Refer overleaf for the Biller Code and Reference Number. The Reference Number is used to identify your holding. If you have multiple holdings you will have multiple Reference Numbers. You must use the Reference Number shown on each personalised Entitlement and Acceptance Form when paying for any New Shares that you wish to apply for in respect of that holding.

#### 2. IF PAYING BY CHEQUE, BANK DRAFT OR MONEY ORDER

Complete all relevant sections of the Entitlement and Acceptance Form USING BLOCK LETTERS. These instructions are cross referenced to each section of the Entitlement and Acceptance Form.

##### A. Acceptance of New Shares

Enter into section A the number of New Shares you wish to apply for. The number of New Shares must be equal to or less than your Entitlement, which is set out overleaf.

##### B. Application for Additional New Shares

You can apply for more New Shares than your Entitlement. Please enter the number of **additional** New Shares above your Entitlement for which you wish to apply into Box B. Your Application for additional New Shares may not be successful (wholly or partially). The decision of Analytica Limited on the number of New Shares to be allocated to you will be final. No interest will be paid on any Application Monies received or returned.

##### C. Total Number of New Shares Subscribed for

To calculate total number of New Shares subscribed for, add Box A and Box B and enter this in Box C.

##### D. Cheque, bank draft or money order details

Enter your cheque, bank draft or money order details in section D. Cheques, bank drafts or money orders must be drawn on an Australian branch of a financial institution in Australian currency, made payable to "Analytica Limited" and crossed "Not Negotiable". Please ensure sufficient cleared funds are held in your account, as your cheque will be banked as soon as it is received. If you provide a cheque or money order for the incorrect amount, Analytica Limited may treat you as applying for as many New Shares and Additional New Shares as your cheque, bank draft or money order will pay for.

##### E. Contact details

Enter your correct telephone number here we may contact you regarding your acceptance of New Shares, if necessary.

DRAFT ONLY  
DO NOT USE

### 3. HOW TO LODGE YOUR ENTITLEMENT AND ACCEPTANCE FORM

A reply paid envelope is enclosed for your use. No postage stamp is required if it is posted in Australia. Alternatively, if you have lost the reply paid envelope, or you have obtained the Offer Booklet electronically, your completed Entitlement and Acceptance Form with the payment for New Shares may be mailed to the postal address, or delivered by hand to the delivery address, set out below. **If paying by BPAY® you do not need to complete or return the Entitlement and Acceptance Form.** You should check the processing cut off-time for BPAY® transactions with your bank, credit union or building society to ensure your payment will be received by the Registry by the close of the offer.

#### Mailing Address

Analytica Limited  
C/- Link Market Services Limited  
GPO Box 3560  
Sydney NSW 2001

#### Hand Delivery

Analytica Limited  
C/- Link Market Services Limited  
1A Homebush Bay Drive  
Rhodes NSW 2138 **(Please do not use this address for mailing purposes)**

Make sure you send your Acceptance Slip and application payment allowing enough time for mail delivery, so Link Market Services Limited receives them no later than 5.00pm (Sydney time) on 31 May 2019. Please ensure sufficient cleared funds are held in your account, as your cheque will be banked as soon as it is received. Analytica Limited reserves the right not to process any Acceptance Slips and cheques received after the Closing Date.

**If you require further information on how to complete this Entitlement and Acceptance Form, please contact the Analytica Limited Offer Information Line on 1300 795 998 (within Australia) or +61 1300 795 998 (from outside Australia) between 8:30am and 5:30pm (Sydney) Monday to Friday.**